By 2017, the market for cosmetic surgery, aesthetic services, and laser treatments may exceed 3 billion dollars in revenue, according to medical research firm iData Research.
Fueled by new botulinum toxin drugs, facial fillers, laser treatments and light based aesthetic treatments, the market could nearly double in size within a few years. Competition between pharmaceutical companies will intensify and drive growth further as new companies enter the market, say researchers.
Allergan, maker of Botox®, Juvederm and Latisse, will no longer have a monopoly on botulinum toxin, as Dysport® and the new PurTox® claim a greater share of the U.S. aesthetics market.
You can read more about the report, “Markets for Cosmetic Surgery, Facial Aesthetics and Medical Laser Devices 2011″ from idataresearch.net or in the official press release.